Abstract
Meropenem is a third generation broad spectrum antibiotic. Emergence of meropenem resistance has been reported due to development of mutant plasmid mediated metallo-β-lactamases (IMP-6) and AmpC β–lactamases. Sulbactam, a stable β-lactamase inhibitor, increase antimicrobial activity of meropenem by inhibiting the enzyme β-lactamase. Fixed dose combination of Meropenem-sulbactam in the proportion of 1:1, 1:2, 1:3, 2:1 and 3:1 were evaluated for the antimicrobial activity. Combination of meropenem and sulbactam in the ratio of 2:1 exhibited the synergistic activity. This combination was checked for the subchronic toxicity on wistar rats and no change in biochemical and physiological parameters was observed.
Highlights
Since the advent of antibiotic these have been used to treat variety of bacterial infection
Prolonged and overuse of antibiotics have led to development of resistance against the several antibiotic in microorganism as a survival strategy
Keeping in the view clinical significance of fixed dose combination of meropenem and sulbactam, we planned to study the antimicrobial activity of the combination and its safety profile
Summary
Since the advent of antibiotic these have been used to treat variety of bacterial infection. Prolonged and overuse of antibiotics have led to development of resistance against the several antibiotic in microorganism as a survival strategy. The gene encoding IMP-6 MBL, a mutant β-lactamase active against the meropenem, was first identified in plasmid pKU501 from Serratia marcescens KU3838 (Yano et al, 2001). Since it has been a major problem for meropenem resistant outbreak due to horizontal gene transfer (Masuda and Ohya 1992, Nordmann and Poirel 2002, Ryoo et al, 2009). Keeping in the view clinical significance of fixed dose combination of meropenem and sulbactam, we planned to study the antimicrobial activity of the combination and its safety profile
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have